Decision: Favourable

Study Title:

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Ph

  • NREC Code:

    21-NREC-CT-003

  • Decision:

    Favourable

  • Meeting Date:

    02/06/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Orla Killeen

  • PI Institution:

    Children's Health Ireland at Crumlin

  • Sponsor:

    Sanofi-aventis Recherche & Développement

Scroll to Top
Skip to content